A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 73,497 shares of AXSM stock, worth $10.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
73,497
Holding current value
$10.1 Million
% of portfolio
0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

BUY
$83.08 - $100.49 $6.11 Million - $7.39 Million
73,497 New
73,497 $6.22 Million
Q4 2023

Feb 09, 2024

BUY
$57.42 - $83.61 $823,345 - $1.2 Million
14,339 New
14,339 $1.14 Million
Q2 2022

Aug 05, 2022

SELL
$21.74 - $46.75 $199,899 - $429,866
-9,195 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$23.7 - $41.39 $217,921 - $380,581
9,195 New
9,195 $381,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $5.91B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.